GlassScriptPhysician profile
Jessicah Todd
NPI 1689450835
$726.89
in general payments reported to CMS, 2019-2025
20 companies · $432 in 2025
The $432 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $295 · 2025: $432.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $727.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $726.89 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $124.96 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $89.10 | 2024-2025 | Caplyta |
| Exact Sciences Corporation | $68.06 | 2024-2025 | Cologuard Collection Kit |
| Abbvie INC. | $60.81 | 2024-2025 | |
| Pfizer INC. | $49.08 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $41.63 | 2024-2025 | |
| Tolmar, INC. | $40.55 | 2024-2025 | Jatenzo |
| Glaxosmithkline, LLC. | $33.11 | 2024-2025 | Trelegy Ellipta, Arexvy |
| Novartis Pharmaceuticals Corporation | $28.42 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $24.00 | 2025 | Gvoke Hypopen |
| Actelion Pharmaceuticals US, INC. | $20.73 | 2024 | Opsumit, Uptravi |
| Teva Pharmaceuticals USA, INC. | $20.51 | 2025 | Austedo Xr |
| Corcept Therapeutics | $20.43 | 2025 | Korlym |
| Otsuka America Pharmaceutical, INC. | $19.44 | 2024 | Rexulti |
| Astrazeneca Pharmaceuticals LP | $16.11 | 2025 | Airsupra |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $14.96 | 2025 | Repatha, Otezla |
| Lilly USA, LLC | $14.37 | 2025 | Mounjaro |
| Astellas Pharma US INC | $14.27 | 2024 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $13.37 | 2024 | Trintellix |
| Phathom Pharmaceuticals, INC. | $12.98 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jessicah Todd listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.